SQZB
vs
S&P 500
SQZB
S&P 500
Over the past 12 months, SQZB has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's +13% growth.
Stocks Performance
SQZB vs S&P 500
Performance Gap
SQZB vs S&P 500
Performance By Year
SQZB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
SQZ Biotechnologies Co
Glance View
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2020-10-30. The firm is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in human papillomavirus (HPV) plus tumors. The company is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that is designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.
